- Energizer Holdings to acquire feminine hygiene business from J&J Family of Consumer Cos.
- Three new Takeda diabetes drugs become available
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Diabetics constantly on the look-out for new ways to manage disease
- Patients on Type 2 diabetes drugs may experience dangerously low blood sugar despite lack of disease control, study finds
BEDFORD, Mass. — Insulet and LifeScan have entered a partnership through which the latter's OneTouch blood-glucose monitoring technology will be integrated into the former's OmniPod Personal Diabetes Manager.
The nonexclusive worldwide agreement, which has an initial term that will run through 2017, will involve LifeScan providing its glucose monitoring technology to Insulet, who will be responsible for the development, design and approval of the integrated device. Insulet, however, maintains an exclusivity option to be declared, at its discretion, upon commercialization of the integrated PDM. This option would make LifeScan the exclusive blood-glucose monitoring technology integrated into the OmniPod PDM and provide additional compensation to Insulet.
"The easy to use, tubeless OmniPod is the most innovative technology available in the insulin pump market, so we are thrilled to integrate with LifeScan's market leading OneTouch blood-glucose monitoring technologies," Insulet president and CEO Duane DeSisto said. "Our team has commenced development efforts on a new PDM which we expect to be commercialized in 2013. The new integrated PDM will work with the next generation OmniPod, which is currently awaiting 510(k) clearance."